Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

Prior treatment

• 2\. Treatment with other anti-cancer therapies and cannot be stopped currently
• 9\. Serious Risks or Serious Adverse Events of the drug product
• 10\. The prohibition of drug products

Other illness

• 5\. The patients with other serious intercurrent illness or infectious diseases
• 6\. Have more than one different kind of cancer at the same time
• 7\. Serious Allergy to Drugs

Other

• 1\. Pneumonectomy
• 3\. Pregnancy
• 4\. Breast-feeding
• 8\. Serious Bleed Tendency
• 11\. Have no therapeutic effects
• 12\. Follow up to the most current label

• 1\. Metastatic ALK-Positive Non-Small Cell Lung Cancer (NSCLC) as follows:
• Took ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily more than 90 days
• Had no further NSCLC metastatic or growth in more than previous 90 days
• 2\. Suitable for enough blood-drawing
• 3\. Sequential Assignment
• 4\. Measurable disease
• 5\. Adequate organ functions
• 6\. Adequate performance status
• 7\. Age 24-64 years old
• 8\. Sign an informed consent form
• 9\. Receive blood-drawing

Criteria the registry did not label

• Select 600 patients with Metastatic ALK-Positive Non-Small Cell Lung Cancer (NSCLC) as follows:
  • Took ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily more than 90 days
  • Had no further NSCLC metastatic or growth in more than previous 90 days
• Dosage Duration at least 90 days
• The usual approach group - Recruit 300 Sequential Assignment group separated NSCLC patients currently used the Chemotherapy NDC...01 on ALECENSA capsule 600 mg orally twice daily, diagnosed metastatic ALK-positive NSCLC, like as the usual approach group.
• The study approach group - Recruit 300 Sequential Assignment group separated NSCLC patients currently used the Chemotherapy NDC...86 on ALECENSA capsule 600 mg orally twice daily, diagnosed metastatic ALK-positive NSCLC, like as the study approach group.